Douglas Bachman - Quest PharmaTech VP Devel
| QPTFF Stock | USD 0.01 0.00 0.00% |
Insider
Douglas Bachman is VP Devel of Quest PharmaTech
| Age | 69 |
| Phone | 780 448 1400 |
| Web | https://www.questpharmatech.com |
Quest PharmaTech Management Efficiency
Quest PharmaTech's management efficiency ratios could be used to measure how well Quest PharmaTech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Dr III | Cue Biopharma | 48 | |
| Elliott Berger | BioCryst Pharmaceuticals | N/A | |
| Merav Bassan | Biomx Inc | 58 | |
| Assaf Oron | Biomx Inc | 50 | |
| Ahmed JD | Pieris Pharmaceuticals | 39 | |
| Sumita JD | Instil Bio | 50 | |
| William MBBS | BioCryst Pharmaceuticals | 69 | |
| Uri MD | Assembly Biosciences | 52 | |
| Adam Zlotnick | Assembly Biosciences | N/A | |
| Patrick Walsh | Immunic | 40 | |
| Richard Waldron | Bioatla | 70 | |
| Ted Jenkins | Spero Therapeutics | N/A | |
| Philippe Martin | Bioatla | 48 | |
| AFPM MD | Trevi Therapeutics | 57 | |
| Jonathan MBA | Biomx Inc | 47 | |
| Thomas MD | Trevi Therapeutics | 71 | |
| Alexander MS | Fennec Pharmaceuticals | N/A | |
| Hitto Kaufmann | Pieris Pharmaceuticals | 53 | |
| Amie Krause | Atara Biotherapeutics | N/A | |
| Steven Almo | Cue Biopharma | 63 | |
| James JD | Eliem Therapeutics | 58 | |
Management Performance
| Return On Equity | -0.62 | |||
| Return On Asset | -0.0038 |
Quest PharmaTech Leadership Team
Elected by the shareholders, the Quest PharmaTech's board of directors comprises two types of representatives: Quest PharmaTech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Quest. The board's role is to monitor Quest PharmaTech's management team and ensure that shareholders' interests are well served. Quest PharmaTech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Quest PharmaTech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Woo, Vice President - Product Development | ||
| Roger Andrews, Head Communications | ||
| Douglas Bachman, VP Devel | ||
| Pierre Vermette, Chief Officer | ||
| Ragupathy Madiyalakan, CEO, Director, Ex-Officio Member of Compensation Committee, Ex-Officio Member of Audit Committee and Ex-Officio Member of Corporate Governance Committee |
Quest Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Quest PharmaTech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.62 | |||
| Return On Asset | -0.0038 | |||
| Current Valuation | 7.81 M | |||
| Shares Outstanding | 169.13 M | |||
| Shares Owned By Insiders | 16.80 % | |||
| Price To Earning | 0.14 X | |||
| Price To Book | 0.19 X | |||
| EBITDA | (84.99 M) | |||
| Net Income | (85.04 M) | |||
| Cash And Equivalents | 518.76 K |
Currently Active Assets on Macroaxis
Other Information on Investing in Quest Pink Sheet
Quest PharmaTech financial ratios help investors to determine whether Quest Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Quest with respect to the benefits of owning Quest PharmaTech security.